Evidence map›Paper›PMID 37645804›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.

Seth A Reasoner, Rachel Bernard, Adam Waalkes, Kelsi Penewit, Janessa Lewis, Andrew G Sokolow, Rebekah F Brown, Kathryn M Edwards, Stephen J Salipante, Maria Hadjifrangiskou and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Seth A ReasonerDivision of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-7791-1641
Rachel BernardDivision of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, TN, USA.ORCID 0000-0002-6689-5658
Adam WaalkesDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-5202-1108
Kelsi PenewitDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Janessa LewisDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Andrew G SokolowDivision of Allergy, and Immunology, and Pulmonary Medicine, Department of Pediatrics, Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, TN, USA.ORCID 0000-0002-5495-1237
Rebekah F BrownDivision of Allergy, and Immunology, and Pulmonary Medicine, Department of Pediatrics, Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, TN, USA.ORCID 0000-0003-3632-4587
Kathryn M EdwardsDivision of Infectious Diseases, Department of Pediatrics, Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, Tennessee, USA.ORCID 0000-0003-3912-9832
Stephen J SalipanteDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID 0000-0001-8355-6992
Maria HadjifrangiskouDivision of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-4249-8997
Maribeth R NicholsonDivision of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Monroe Carrell Junior Children's Hospital at Vanderbilt, Nashville, TN, USA.ORCID 0000-0003-3941-5599
Monroe Carell Jr. Children's Hospital · USUniversity of Washington · USVanderbilt University Medical Center · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Sonya Heltshe · 2010 to 2026
$21.4M
TRAINING IN GASTROENTEROLOGYT32DK007673 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 1992 to 2026
$8.4M
Immune, Microbial, and Metabolic Factors that Impact Clostridioides difficile and Inflammatory Bowel Disease in ChildrenK23AI156132 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NICHOLSON, MARIBETH RUTH · 2021 to 2025
$876k
Copper Sensing in Uropathogenic Escherichia coliF30AI169748 · NIAID · VANDERBILT UNIVERSITY · PI Seth A Reasoner · 2023 to 2026
$156k
NIAID NIH HHS F30 AI169748NIAID NIH HHS K23 AI156132NIDDK NIH HHS P30 DK089507NIDDK NIH HHS T32 DK007673NIGMS NIH HHS T32 GM007347
6 · The paper itself

Abstract

The intestinal microbiome influences growth and disease progression in children with cystic fibrosis (CF). Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA), the newest pharmaceutical modulator for CF, restores function of the pathogenic mutated CFTR channel. We performed a single-center longitudinal analysis of the effect of ELX/TEZ/IVA on the intestinal microbiome, intestinal inflammation, and clinical parameters in children with CF. Following ELX/TEZ/IVA, children with CF had significant improvements in BMI, ppFEV

Indexed as

antibiotic resistanceCFTR modulatorsCystic fibrosiselexacaftorintestinal inflammationivacaftormetagenomic sequencingmicrobiomepediatrictezacaftor

Identifiers

PMID37645804
PMCPMC10462202
OpenAlexW4385953128

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.